Tags

Type your tag names separated by a space and hit enter

Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Leuk Lymphoma 2019; 60(9):2271-2277LL

Abstract

Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI). This was a retrospective cohort study of adult lymphoma patients at intermediate or high risk for TLS. Excluded patients had AKI or were on dialysis at hospital admission. The incidence of new AKI in the setting of TLS was described along with predictors of its development, including early rasburicase use. In 383 included patients, the incidence of new-onset AKI during hospitalization was 6%. Predictors included age, history of renal or cardiovascular disease, and UA >8 mg/dL. Rasburicase use did not significantly impact the risk of developing AKI (HR 2.3; p = .11). The UA level at the time of administration did not modify the effect of rasburicase on prevention of AKI (p = .36 for the interaction term).

Authors+Show Affiliations

Department of Pharmacy, Mayo Clinic , Rochester , MN , USA.Department of Pharmacy, Mayo Clinic , Rochester , MN , USA. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.Department of Pharmacy, Mayo Clinic , Rochester , MN , USA.Division of Biomedical Statistics and Informatics, Mayo Clinic , Rochester , MN , USA.Division of Nephrology and Hypertension and Division of Hematology, Mayo Clinic , Rochester , MN , USA. Division of Hematology, Mayo Clinic , Rochester , MN , USA.Division of Hematology, Mayo Clinic , Rochester , MN , USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31223041

Citation

Personett, Heather A., et al. "Impact of Early Rasburicase On Incidence of Clinical Tumor Lysis Syndrome in Lymphoma." Leukemia & Lymphoma, vol. 60, no. 9, 2019, pp. 2271-2277.
Personett HA, Barreto EF, McCullough KB, et al. Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. Leuk Lymphoma. 2019;60(9):2271-2277.
Personett, H. A., Barreto, E. F., McCullough, K. B., Dierkhising, R., Leung, N., & Habermann, T. M. (2019). Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. Leukemia & Lymphoma, 60(9), pp. 2271-2277. doi:10.1080/10428194.2019.1574000.
Personett HA, et al. Impact of Early Rasburicase On Incidence of Clinical Tumor Lysis Syndrome in Lymphoma. Leuk Lymphoma. 2019;60(9):2271-2277. PubMed PMID: 31223041.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. AU - Personett,Heather A, AU - Barreto,Erin F, AU - McCullough,Kristen B, AU - Dierkhising,Ross, AU - Leung,Nelson, AU - Habermann,Thomas M, Y1 - 2019/06/21/ PY - 2019/6/22/pubmed PY - 2019/6/22/medline PY - 2019/6/22/entrez KW - Lymphoma and Hodgkin disease KW - acute kidney injury KW - lymphoid leukemia KW - pharmacotherapeutics KW - rasburicase KW - tumor lysis syndrome SP - 2271 EP - 2277 JF - Leukemia & lymphoma JO - Leuk. Lymphoma VL - 60 IS - 9 N2 - Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI). This was a retrospective cohort study of adult lymphoma patients at intermediate or high risk for TLS. Excluded patients had AKI or were on dialysis at hospital admission. The incidence of new AKI in the setting of TLS was described along with predictors of its development, including early rasburicase use. In 383 included patients, the incidence of new-onset AKI during hospitalization was 6%. Predictors included age, history of renal or cardiovascular disease, and UA >8 mg/dL. Rasburicase use did not significantly impact the risk of developing AKI (HR 2.3; p = .11). The UA level at the time of administration did not modify the effect of rasburicase on prevention of AKI (p = .36 for the interaction term). SN - 1029-2403 UR - https://www.unboundmedicine.com/medline/citation/31223041/Impact_of_early_rasburicase_on_incidence_of_clinical_tumor_lysis_syndrome_in_lymphoma L2 - http://www.tandfonline.com/doi/full/10.1080/10428194.2019.1574000 DB - PRIME DP - Unbound Medicine ER -